RecruitingNot ApplicableNCT07499765
Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis
Benefits of Formalized Care Support Program Following an Annoucement of Acute Leukemia Diagnosis
Sponsor
Centre Henri Becquerel
Enrollment
110 participants
Start Date
Mar 30, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine the impact on anxiety between patients with a period of care support following their announcement of an acute leukemia (AL) diagnosis and patients without this accompaniment.
Eligibility
Min Age: 26 YearsMax Age: 80 Years
Inclusion Criteria6
- informed consent signed
- medical confirmation of acute leukemia diagnosis
- age equal of superior to 26 years and under 80 years
- confirmed diagnosis not yet treated
- hospitalization at Centre Henri Becquerel
- member or beneficiary of a social security
Exclusion Criteria8
- Patient unable to understand the study for any reason or to comply with the trial's requirements
- Patient in relapse of acute leukemia
- Patient diagnosed with acute myeloid leukemia 3
- History of cancer within the 5 years preceding the year of study enrollment
- Alcohol and drug abuse
- Inclusion in another therapeutic trial that prevents further enrollment in a trial evaluating quality of life or psychological well-being
- Diagnosed psychiatric illness
- Patient under guardianship, curatorship, or legal protection
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERcare support program after diagnosis announcement
a dedicated time with a specialized nurse in announcement will be given tot the patient. The anxiety will also be evaluated
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07499765
Related Trials
A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT
NCT075596951 location
Familial Investigations of Childhood Cancer Predisposition
NCT030502681 location
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560103 locations
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
NCT074935381 location
Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.
NCT063569224 locations